Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29070 | 0.90 | GPR119 (0.51) | SPHK1GPR119SPHK2 | |
| SCHEMBL29071 | 0.90 | GPR119 (0.51) | SPHK1GPR119SPHK2 | |
| SCHEMBL25170389 | 0.84 | SPHK1 (0.48) | SPHK1GPR119HDAC4HDAC6SPHK2 | |
| SCHEMBL29308060 | 0.84 | SPHK1 (0.48) | SPHK1GPR119HDAC4HDAC6SPHK2 | |
| SCHEMBL4152457 | 0.84 | GRM5 (0.55) | SPHK1GRM5SPHK2SIRT2CLPP | |
| SCHEMBL25171095 | 0.81 | SPHK2 (0.58) | SPHK1GPR119SPHK2 | |
| SCHEMBL25176627 | 0.80 | SPHK2 (0.72) | SPHK1GPR119SPHK2 | |
| SCHEMBL25174342 | 0.80 | SPHK2 (0.63) | SPHK1HDAC4HDAC6SPHK2 | |
| SCHEMBL25171154 | 0.79 | SPHK2 (0.60) | SPHK1GPR119SPHK2 | |
| SCHEMBL25177129 | 0.79 | SPHK2 (0.75) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2009-08-06 | — | — | US | disclosed |
| EP-1896463-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006123249-A2 | NOVEL OXADIAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197897-A1 | Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM3 | SPHK1 2380/4885GPR119 76/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.